These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 9469328)

  • 61. [CGS 20267 (Letrozole), a new aromatase inhibitor: early phase II study for postmenopausal women with advanced breast cancer].
    Nomura Y; Tominaga T; Enomoto K; Aoyama H; Nakamura Y; Abe R; Sano M; Nomizu T; Tohge T; Takashima S; Ohashi Y
    Gan To Kagaku Ryoho; 2002 Apr; 29(4):551-62. PubMed ID: 11977539
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Static disease on anastrozole provides similar benefit as objective response in patients with advanced breast cancer.
    Robertson JF; Howell A; Buzdar A; von Euler M; Lee D
    Breast Cancer Res Treat; 1999 Nov; 58(2):157-62. PubMed ID: 10674881
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Letrozole (CGS 20267), a new oral aromatase inhibitor for the treatment of advanced breast cancer in postmenopausal patients.
    Trunet PF; Bhatnagar AS; Chaudri HA; Hornberger U
    Acta Oncol; 1996; 35 Suppl 5():15-8. PubMed ID: 9142959
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Goserelin plus letrozole as first- or second-line hormonal treatment in premenopausal patients with advanced breast cancer.
    Yao S; Xu B; Li Q; Zhang P; Yuan P; Wang J; Ma F; Fan Y
    Endocr J; 2011; 58(6):509-16. PubMed ID: 21532215
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Exemestane improves survival in metastatic breast cancer: results of a phase III randomized study.
    Kaufmann M; Bajetta E; Dirix LY; Fein LE; Jones SE; Zilembo N; Dugardyn JL; Nasurdi C; Mennel RG; Cervek J; Fowst C; Polli A; di Salle E; Arkhipov A; Piscitelli G; Miller LL; Massimini G
    Clin Breast Cancer; 2000 Sep; 1 Suppl 1():S15-8. PubMed ID: 11970744
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Letrozole as primary medical therapy for locally advanced and large operable breast cancer.
    Dixon JM; Love CD; Bellamy CO; Cameron DA; Leonard RC; Smith H; Miller WR
    Breast Cancer Res Treat; 2001 Apr; 66(3):191-9. PubMed ID: 11510690
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741.
    Abrams J; Aisner J; Cirrincione C; Berry DA; Muss HB; Cooper MR; Henderson IC; Panasci L; Kirshner J; Ellerton J; Norton L
    J Clin Oncol; 1999 Jan; 17(1):64-73. PubMed ID: 10458219
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Comparing the Administration of Letrozole and Megestrol Acetate in the Treatment of Women with Simple Endometrial Hyperplasia without Atypia: A Randomized Clinical Trial.
    Moradan S; Nikkhah N; Mirmohammadkhanai M
    Adv Ther; 2017 May; 34(5):1211-1220. PubMed ID: 28353144
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Cost effectiveness of letrozole in the treatment of advanced breast cancer in postmenopausal women in the UK.
    Nuijten M; Meester L; Waibel F; Wait S
    Pharmacoeconomics; 1999 Oct; 16(4):379-97. PubMed ID: 10623366
    [TBL] [Abstract][Full Text] [Related]  

  • 70. A Phase II Clinical Trial of an Aromatase Inhibitor for Postmenopausal Women with Lymphangioleiomyomatosis.
    Lu C; Lee HS; Pappas GP; Dilling DF; Burger CD; Shifren A; Veeraraghavan S; Chapman JT; Parambil J; Ruoss SJ; Young LR; Hammes SR; Kopras EJ; Roads T; Krischer JP; McCormack FX;
    Ann Am Thorac Soc; 2017 Jun; 14(6):919-928. PubMed ID: 28570161
    [TBL] [Abstract][Full Text] [Related]  

  • 71. High- versus standard-dose megestrol acetate in women with advanced breast cancer: a phase III trial of the Piedmont Oncology Association.
    Muss HB; Case LD; Capizzi RL; Cooper MR; Cruz J; Jackson D; Richards F; Powell BL; Spurr CL; White D
    J Clin Oncol; 1990 Nov; 8(11):1797-805. PubMed ID: 2230868
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Letrozole: updated duration of response.
    Chaudri HA; Trunet PF
    J Clin Oncol; 1999 Dec; 17(12):3856-60. PubMed ID: 10577865
    [No Abstract]   [Full Text] [Related]  

  • 73. Activity of megestrol acetate in postmenopausal women with advanced breast cancer after nonsteroidal aromatase inhibitor failure: a phase II trial.
    Bines J; Dienstmann R; Obadia RM; Branco LGP; Quintella DC; Castro TM; Camacho PG; Soares FA; Costa MEF
    Ann Oncol; 2014 Apr; 25(4):831-836. PubMed ID: 24615412
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer.
    Lipton A; Demers LM; Harvey HA; Kambic KB; Grossberg H; Brady C; Adlercruetz H; Trunet PF; Santen RJ
    Cancer; 1995 Apr; 75(8):2132-8. PubMed ID: 7697604
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Effect of letrozole on the lipid profile in postmenopausal women with breast cancer.
    Elisaf MS; Bairaktari ET; Nicolaides C; Kakaidi B; Tzallas CS; Katsaraki A; Pavlidis NA
    Eur J Cancer; 2001 Aug; 37(12):1510-3. PubMed ID: 11506958
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Increased pathological complete response rate after a long-term neoadjuvant letrozole treatment in postmenopausal oestrogen and/or progesterone receptor-positive breast cancer.
    Allevi G; Strina C; Andreis D; Zanoni V; Bazzola L; Bonardi S; Foroni C; Milani M; Cappelletti MR; Gussago F; Aguggini S; Giardini R; Martinotti M; Fox SB; Harris AL; Bottini A; Berruti A; Generali D
    Br J Cancer; 2013 Apr; 108(8):1587-92. PubMed ID: 23579222
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Letrozole withdrawal response in locally advanced breast cancer.
    Lambertini M; Pronzato P; Giraudi S; Levaggi A; Bighin C; Del Mastro L
    Ann Oncol; 2011 Aug; 22(8):1927-8. PubMed ID: 21562073
    [No Abstract]   [Full Text] [Related]  

  • 78. Double-Blind, Randomized Trial of Alternative Letrozole Dosing Regimens in Postmenopausal Women with Increased Breast Cancer Risk.
    López AM; Pruthi S; Boughey JC; Perloff M; Hsu CH; Lang JE; Ley M; Frank D; Taverna JA; Chow HH
    Cancer Prev Res (Phila); 2016 Feb; 9(2):142-8. PubMed ID: 26667449
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Randomized trial of vitamin D3 to prevent worsening of musculoskeletal symptoms in women with breast cancer receiving adjuvant letrozole. The VITAL trial.
    Khan QJ; Kimler BF; Reddy PS; Sharma P; Klemp JR; Nydegger JL; Yeh HW; Fabian CJ
    Breast Cancer Res Treat; 2017 Nov; 166(2):491-500. PubMed ID: 28770449
    [TBL] [Abstract][Full Text] [Related]  

  • 80. False shortening of time to progression in letrozole 2.5-mg dose?
    Cocconi G
    J Clin Oncol; 2001 Dec; 19(23):4353; author reply 4354-5. PubMed ID: 11731525
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.